Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$5.67 USD
-0.41 (-6.74%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.67 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/11/2025
Time: -- |
9/2025 | $-0.30 | 0.00% |
Earnings Summary
For their last quarter, Terns Pharmaceuticals (TERN) reported earnings of -$0.26 per share, beating the Zacks Consensus Estimate of $-0.28 per share. This reflects a positive earnings surprise of 7.14%. Look out for TERN's next earnings release expected on November 11, 2025. For the next earning release, we expect the company to report earnings of -$0.30 per share, reflecting a year-over-year decrease of 7.14%.
Earnings History
Price & Consensus
Zacks News for TERN
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
TERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
TERN FAQs
Based on past history, Zacks believes Terns Pharmaceuticals, Inc. (TERN) will report their next quarter earnings on November 11, 2025. For the next earning release, we expect the company to report earnings of -0.30 per share, reflecting a year-over-year increase of -7.14.
Based on past history, Zacks believes Terns Pharmaceuticals, Inc. (TERN) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 11, 2025.
The Zacks Consensus Estimate for Terns Pharmaceuticals, Inc. (TERN) for the quarter ending September 2025 is $-0.30 a share. We expect Terns Pharmaceuticals, Inc. (TERN) to report earnings in line with the consensus estimate of $-0.30 per share
In the earnings report for the quarter ending in June 2024, Terns Pharmaceuticals, Inc. (TERN) announced earnings of $-0.31 per share versus the Zacks Consensus Estimate of $-0.35 per share, representing a surprise of -11.43%.